April 13, 2021 SynAct stärker IP-portföljen och får “Intention to Grant” från Europas patentverk för ett centralt patent som täcker AP1189 March 18, 2021 SynAct has initiated dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients UK version

SynAct strengthens IP portfolio – Receives “Intention to Grant” from the European Patent Office for a key patent covering AP1189 English version; Omvänd vinstvarning från diagnostikjätten Medicover; Nordisk Proptech får eget branschpris: "Fintech-investeringar flyttar över mot proptech"

Forskningsbolaget Synact Pharma har erhållit en "Intention to Grant", en form av avsiktsförklaring, från Europas patentverk för att patentera läkemedelskandidaten AP1189 metoder att behandla njursjukdomar. Det framgår av ett pressmeddelande. Vissa formaliteter måste fortfarande följas innan ett giltigt patent delas ut. SynAct Pharma AB (“SynAct”) today announces that the company has filed an international patent application under the Patent Coordination Treaty (PCT), to cover combination treatment with the company’s lead compound AP1189 and Methotrexate (MTX) for treatment of Rheumatoid Arthritis (RA) and other arthritic diseases. 2021-04-13 · SynAct has received information that the company obtained an “Intention to grant” from the EPO regarding their patent application 19734023.5 (EP publication 3743064) which concerns the use of AP1189 in methods of treating kidney disease, specifically primary nephrotic syndrome, including membranous nephropathy as is currently tested in clinical trials. SynAct Pharma files patent application for combination of AP1189 and Methotrexate for treatment of RA and other arthritic diseases The application was filed in continuation of a preliminary European patent application the company filed in May 2019. SynAct Pharma applies for patent for AP1189 within COVID-19 Fri, Apr 03, 2020 10:06 CET SynAct Pharma AB ("SynAct") hereby announces that the company has filed a patent application to the European Patent Office (EPO) covering the use of AP1189 for the treatment of COVID-19 infection, including Acute Respiratory Distress Syndrome (ARDS) and Systemic Inflammatory Response Syndrome (SIRS).

SynAct Pharma files patent application for combination of AP1189 and Methotrexate for treatment of RA and other arthritic diseases The application was filed in continuation of a preliminary European patent application the company filed in May 2019. SynAct Pharma applies for patent for AP1189 within COVID-19 Fri, Apr 03, 2020 10:06 CET SynAct Pharma AB ("SynAct") hereby announces that the company has filed a patent application to the European Patent Office (EPO) covering the use of AP1189 for the treatment of COVID-19 infection, including Acute Respiratory Distress Syndrome (ARDS) and Systemic Inflammatory Response Syndrome (SIRS). SynAct Pharma AB ('SynAct') today announces that the company has filed an international patent application under the Patent Coordination Treaty (PCT), to cover combination treatment with the compan AP1189 –a melanocortin receptor agonist to reduce inflammation and “boost” healing First indication: activeinflammatory joint diseases (rheumatoid and psoriatic arthritis) Opportunity: additional indications based on Mode of Action (ACTH-like properties) April 13, 2021 SynAct stärker IP-portföljen och får “Intention to Grant” från Europas patentverk för ett centralt patent som täcker AP1189. March 18, 2021 SynAct has initiated dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients UK version. Synact Pharma ansöker om patent för AP1189 för behandling av covid-19 03 april 2020 kl 10:21 Forskningsbolaget Synact Pharma har lämnat in en ansökan till det europeiska patentverket EPO för användningen av bolagets läkemedelskandidat AP1189 för behandling av sjukdomen covid-19, inklusive ards och sirs. SynAct Pharma applies for patent for AP1189 within COVID-19 SynAct Pharma AB ("SynAct") hereby announces that the company has filed a patent application to the European Patent Office (EPO) covering. .

SynAct Pharma AB today announces that the company has filed an international patent application under the Patent Coordination Treaty , to cover combination treatment with the company's lead compound SynAct Pharma applies for patent for AP1189 within COVID-19 03 April 2020 - 10:06 SynAct Pharma AB ("SynAct") hereby announces that the company has filed a patent application to the European Patent Office (EPO) covering the use of AP1189 for the treatment of COVID-19 infection, including Acute Respiratory Distress Syndrome (ARDS) and Systemic Inflammatory Response Syndrome (SIRS). SynAct Pharma räknar med att inom kort erhålla godkännande för att kunna inleda en klinisk fas II-studie i Covid-19-patienter med läkemedelskandidaten AP1189. Dessutom har man gläntat på dörren för att undersöka kandidatens potential i ytterligare virussjukdomar.

Patent Office (EPO) issued an 'Intention to grant' for SynAct's patent application covering the company's leading drug candidate AP1189

Synact Pharma. Forskningsbolaget Synact Pharma har erhållit en "Intention to Grant", en form av avsiktsförklaring, från Europas patentverk för att patentera läkemedelskandidaten AP1189 metoder att behandla njursjukdomar.

* synact pharma applies for patent for ap1189 within covid-19 * synact pharma ab - filed a patent application to european patent office (epo) covering use of ap1189 for treatment of covid-19

SynAct has received information that the company obtained an “Intention to grant” from the EPO regarding their patent application 19734023.5 (EP publication 3743064) which concerns the use of AP1189 in methods of treating kidney disease, specifically primary nephrotic syndrome, including membranous nephropathy as is currently tested in clinical trials.

SynAct Pharma applies for patent for AP1189 within COVID-19 On March 31, 2020, SynAct announced that the company intends to investigate the possibility of applying AP1189 to clinics through potential funding from government institutions and commercial partners operating in the COVID-19 area. SynAct Pharma AB hereby announces that the company has filed a patent application to the European Patent Office covering the use of AP1189 for the treatment of COVID-19 infection, including Acute SynAct Pharma SynAct strengthens IP portfolio – Receives “Intention to Grant” from the European Patent Office for a key patent covering AP1189. SynAct Pharma SynAct carries out a directed share issue and raises proceeds of SEK 80 million. tis, apr 13, 2021 13:57 CET. SynAct Pharma AB (“SynAct”) tillkännagav i dag att European Patent Office (EPO) utfärdat en ”Intention to Grant” för SynAct patentansökan som täcker bolagets ledande läkemedelskandidat AP1189 för metoder att behandla njursjukdomar.
Sell in amazon

2021-04-13 SynAct Pharma AB ('SynAct') hereby announces that the company has filed a patent application to the European Patent Office (EPO) covering the use of AP1189 for the treatment of COVID-19 infection, Hence, the model mimics active stages of RA, where AP1189 currently is tested in Phase II as add-on treatment to MTX. AP1189 has previously been tested in the model (see J Immunol. 194:3381-8, 2015), and in the new dataset filed with the patent application the compound, at a sub maximal dose was given in combination with MTX. * synact pharma applies for patent for ap1189 within covid-19 * synact pharma ab - filed a patent application to european patent office (epo) covering use of ap1189 for treatment of covid-19 infection SynAct Pharma applies for patent for AP1189 within COVID-19. SynAct Pharma AB ("SynAct") hereby announces that the company has filed a patent application to the European Patent Office (EPO) covering. . Läs mer på DI Läs mer om: Pharma, AP1189, COVID, Pharma AB, European Patent Office, EPO. Approved patents in US, EU and Japan Experienced Management and Board Expertise in melanocortinresearch, clinical development and global deal making AP1189 Clinical development Phase l 2017/18 (Healthy volunteers ) Phase ll 2018/19 (Patients) Commercial agreement 2 SynAct Pharma applies for patent for AP1189 within COVID-19 Fri, Apr 03, 2020 10:06 CET. SynAct Pharma AB ("SynAct") hereby announces that the company has filed a patent application to the European Patent Office (EPO) covering the use of AP1189 for the treatment of COVID-19 infection, including Acute Respiratory Distress Syndrome (ARDS) and Systemic Inflammatory Response Syndrome (SIRS).

Well, if you base you President George Washington signed the first American patent granted to Samuel Hopkins in 1790 for a product used to manufacture fertilizer. The U.S. Patent and Trademark Office now recognizes more than six million patents. Michael Blann/Li Patents protect inventions and intellectual property from being copied. Learn about the uses of patents, the history of patents and about intellectual property law.
Tennessee james toth

SynAct Pharma applies for patent for AP1189 within COVID-19 SynAct Pharma AB ("SynAct") hereby announces that the company has filed a patent application to the European Patent Office (EPO) covering. .

Applications from Europe grew modestly overall, with marked differences among the larger economies. A mining claim gives a claimant the right to remove mineral deposits that are discovered on a parcel of land. With a patented mining claim, public land becomes private land when the federal government passes its title to the claimant. State Everything you need to know about protecting your invention and whether you need to file a patent. When it comes to inventing, the very first thing you need to do is protect your idea before anyone can steal it, right? Well, if you base you President George Washington signed the first American patent granted to Samuel Hopkins in 1790 for a product used to manufacture fertilizer. The U.S. Patent and Trademark Office now recognizes more than six million patents.